ArticleTherapeutic advances in urology
Characteristics, treatment patterns, and outcomes of patients with metastatic prostate cancer during 2014-2022 in Pirkanmaa, Finland-an observational study.
Article in Therapeutic advances in urology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05701007 (Real World Evidence Study on Metastatic Prostate Cancer Patient Characteristics, Treatment Patterns and Outcomes in the Pirkanmaa Hospital District in Finland), which is not on this map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Real World Evidence Study on Metastatic Prostate Cancer Patient Characteristics, Treatment Patterns and Outcomes in the Pirkanmaa Hospital District in Finland
Who cites it
1 citing paper in PubMed.
- Standard Therapy Plus Adjunctive Vegan Lifestyle Intervention in Metastatic Prostate Cancer: A Case Report.Current oncology (Toronto, Ont.) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The prognosis of patients with metastatic prostate cancer (mPC) has changed profoundly in recent years. However, observational studies are required to understand the real-world outcomes of patients with mPC. Objectives: In this retrospective single-center observational study, we aimed to describe characteristics, treatments, and outcomes of patients with mPC in Pirkanmaa Hospital District (PHD), Finland, an area with a population of 0.5 million (10% of the Finnish population). Design: The incident patients with mPC treated in PHD during 2014-2022 were identified and stratified into patients with metastatic hormone-sensitive PC (mHSPC) and castration-resistant disease PC (mCRPC). Methods: Patients with mPC were identified from electronic healthcare data using diagnoses, treatments, procedures, and patient texts. Data on demographics, diagnoses, procedures, treatments, laboratory and pathology tests, and specialized healthcare contacts were collected from specialty care records. Due to changes in treatment practices over time, treatments and outcomes were analyzed in different time periods (mHSPC: 2014-2016 and 2017-2022, mCRPC: 2014-2017 and 2018-2022). Results: In total, 1083 incident patients with mPC were identified, of which 88% received treatment indicated for mPC. Out of the 795 patients with mHSPC, and 558 patients with mCRPC, 84% ( Conclusion: Since the approval of enzalutamide as a first-line treatment for mCRPC, it has become the most common first-line treatment for mCRPC in PHD. Novel therapeutics, including docetaxel, enzalutamide, and abiraterone, have been adapted into clinical practice and are being used at earlier phases of the disease. Changes in treatment practices correlate with improved outcomes in patients with mHSPC in the PHD area. Trial registration: ClinicalTrials.gov NCT05701007.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.